Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance

Alicia Prieto,Manuel De Barrio,Elena Martín,María Fernández-Bohórquez,Francisco Javier de Castro,Francisco Javier Ruiz,Teresa Herrero,Pilar Tornero,María Rubio
DOI: https://doi.org/10.1016/j.jaci.2006.12.616
Abstract:Background: Because nonsteroidal anti-inflammatory drug (NSAID) intolerance depends on COX-1 inhibition, preferential or selective COX-2 inhibitors have been thought to be well tolerated by these patients. Objective: The aim of this study is to evaluate tolerability to nabumetone and meloxicam in patients with NSAID intolerance. Methods: Seventy patients intolerant to NSAIDs were selected. Thirty subjects were patients with asthma with respiratory (rhinitis-asthma) intolerance to NSAIDs (group A); 40 patients (group B) had cutaneous-mucous (urticaria-angioedema) NSAID intolerance. Diagnosis was based on clinical histories in all patients, and it was confirmed by positive single-blind placebo-controlled oral challenge test in 36 patients. After written informed consent, a single-blind placebo-controlled oral challenge test with nabumetone in all patients (2 g except for 11 patients who reached 1 g) and meloxicam (15 mg) in 51 patients was performed. Results: Of the total selected, 94.3% tolerated 1 g nabumetone. In those who reached the 2-g dose, the tolerability was 83.6%. With respect to meloxicam, 96.1% of patients, tolerated 15 mg. No significant difference in nabumetone and meloxicam tolerability was observed between groups A and B. Conclusion: The results of this study confirm a high percentage of tolerability to the maximum therapeutic dosage of nabumetone and meloxicam in patients with NSAID intolerance, both in those with cutaneous/mucous manifestations and in those with respiratory disease. Clinical implications: Nabumetone and meloxicam are safe alternatives in NSAID-intolerant patients.
What problem does this paper attempt to address?